ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway

@article{Ou2012ROS1AA,
  title={ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway},
  author={S. Ou and Jackie Tan and Y. Yen and R. Soo},
  journal={Expert Review of Anticancer Therapy},
  year={2012},
  volume={12},
  pages={447 - 456}
}
ROS1 is one of 58 receptor tyrosine kinases, and one of two orphan receptor tyrosine kinases where its ligand is unknown. ROS1 is evolutionarily related to ALK. ROS1 rearrangement was discovered in glioblastoma in 1987, in non-small-cell lung cancer (NSCLC) in 2007, and in cholangiocarcinoma in 2011. While the clinicopathologic characteristics of ROS1-rearranged glioblastoma and cholangiocarcinoma patients remain to be defined, the clinicopathologic characteristics of ROS1-rearranged NSCLC… Expand
97 Citations
ALK and ROS1 as a joint target for the treatment of lung cancer: a review.
  • 26
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor
  • 62
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers
  • 72
  • PDF
Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.
  • 34
  • PDF
[Clinical significance of ROS1 rearrangements in non-small cell lung cancer].
  • 2
Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer
  • Leow Pay Chin, R. Soo, R. Soong, S. Ou
  • Medicine
  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2012
  • 112
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
  • 95
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 64 REFERENCES
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer
  • 29
ROS1 rearrangements define a unique molecular class of lung cancers.
  • K. Bergethon, A. Shaw, +19 authors A. Iafrate
  • Biology, Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
  • 430
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
  • 2,879
  • PDF
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
  • 488
  • PDF
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
  • 254
  • PDF
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
  • 1,036
  • PDF
RET, ROS1 and ALK fusions in lung cancer
  • 1,007
The biology and treatment of EML4-ALK non-small cell lung cancer.
  • 450
...
1
2
3
4
5
...